These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

43 related items for PubMed ID: 2547349

  • 1. Cardiovascular action of penta-O-ethylquercetin in the rat.
    Cheav SL, Prigent AF, Picq M, Foussard-Blanpin O, Pacheco H.
    Arch Int Pharmacodyn Ther; 1989; 298():108-24. PubMed ID: 2547349
    [Abstract] [Full Text] [Related]

  • 2. Pentasubstituted quercetin analogues as selective inhibitors of particulate 3':5'-cyclic-AMP phosphodiesterase from rat brain.
    Picq M, Prigent AF, Némoz G, André AC, Pacheco H.
    J Med Chem; 1982 Oct; 25(10):1192-8. PubMed ID: 6292419
    [Abstract] [Full Text] [Related]

  • 3. Effect of two flavonoid compounds on central nervous system. Analgesic activity.
    Picq M, Cheav SL, Prigent AF.
    Life Sci; 1991 Oct; 49(26):1979-88. PubMed ID: 1660953
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of the different cyclic nucleotide phosphodiesterase isoforms separated from rat brain by flavonoid compounds.
    Picq M, Dubois M, Prigent AF, Némoz G, Pacheco H.
    Biochem Int; 1989 Jan; 18(1):47-57. PubMed ID: 2541724
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of cardiac phosphodiesterase III by the novel cardiotonic agent 6-[4-(4'-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride.
    Sellin LC, Alajoutsijärvi A, Törnquist K, Fraser M, Pippuri A, Ojala I.
    Arzneimittelforschung; 1988 Dec; 38(12):1787-9. PubMed ID: 2854467
    [Abstract] [Full Text] [Related]

  • 6. Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine.
    Thomas NJ, Carcillo JA, Herzer WA, Mi Z, Jackson EK.
    J Pharmacol Exp Ther; 2001 Jan; 296(1):168-74. PubMed ID: 11123377
    [Abstract] [Full Text] [Related]

  • 7. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
    Pagani ED, Dundore RL, Bode DC, Bacon ER, Singh B, Lesher GY, Buchholz RA, Silver PJ.
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
    [Abstract] [Full Text] [Related]

  • 8. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
    Alvarez R, Banerjee GL, Bruno JJ, Jones GL, Littschwager K, Strosberg AM, Venuti MC.
    Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
    [Abstract] [Full Text] [Related]

  • 9. Inhibitory effect of some flavonoids and falvonoid mixtures on cyclic AMP phosphodiesterase activity of rat heart.
    Petkov E, Nikolov N, Uzunov P.
    Planta Med; 1981 Oct; 43(2):183-6. PubMed ID: 6273955
    [No Abstract] [Full Text] [Related]

  • 10. Microdialysis of noradrenaline in rostral ventrolateral medulla after intravenous methionine enkephalin administration in anesthetized rats.
    Rhee HM, Strickland JA, Mason PA.
    Can J Cardiol; 1992 Jun; 8(5):527-35. PubMed ID: 1617531
    [Abstract] [Full Text] [Related]

  • 11. [Action of glycerolformal on the cardiovascular system].
    Cheav SL, Salloum S, Pieri F, Kirkiacharian S.
    Ann Pharm Fr; 1985 Jun; 43(5):491-503. PubMed ID: 3835839
    [No Abstract] [Full Text] [Related]

  • 12. Cardiovascular effects of rat calcitonin gene-related peptide in the conscious rat.
    Sirén AL, Feuerstein G.
    J Pharmacol Exp Ther; 1988 Oct; 247(1):69-78. PubMed ID: 2459371
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC, Shih CM, Lai YH, Chen JH, Huang HL.
    Biochem Pharmacol; 2004 Nov 15; 68(10):2087-94. PubMed ID: 15476679
    [Abstract] [Full Text] [Related]

  • 14. Peripheral and central cardiovascular effects of ketanserin in conscious normotensive rats.
    Davy M, Midol-Monnet M, Heimburger M, Beslot F, Cohen Y.
    Arch Int Pharmacodyn Ther; 1987 Dec 15; 290(2):193-206. PubMed ID: 3128194
    [Abstract] [Full Text] [Related]

  • 15. Differentiation of inodilatory responses by non-invasive measures of cardiovascular performance in healthy man.
    De Mey C, Erb K, Schroeter V, Belz GG.
    Int J Clin Pharmacol Ther; 1996 Dec 15; 34(12):525-32. PubMed ID: 8996846
    [Abstract] [Full Text] [Related]

  • 16. Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.
    Sacco G, Evangelista S, Criscuoli M, Goso C, Bigioni M, Binaschi M, Manzini S, Maggi CA.
    Eur J Pharmacol; 2005 Mar 28; 511(2-3):167-74. PubMed ID: 15792785
    [Abstract] [Full Text] [Related]

  • 17. Analysis of the cardiovascular effects of co-derocrine (Hydergine).
    Clark BJ, Bucher T, Waite R.
    J Pharmacol; 1985 Mar 28; 16 Suppl 3():101-11. PubMed ID: 2869189
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity.
    Nagata K, Ogawa T, Omosu M, Fujimoto K, Hayashi S.
    Arzneimittelforschung; 1985 Mar 28; 35(7):1034-6. PubMed ID: 2996562
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological activities of the main metabolite of flavoxate 3-methylflavone-8-carboxylic acid.
    Cazzulani P, Pietra C, Abbiati GA, Ceserani R, Oliva D, Civelli M, Tajana A, Nardi D.
    Arzneimittelforschung; 1988 Mar 28; 38(3):379-82. PubMed ID: 2838033
    [Abstract] [Full Text] [Related]

  • 20. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
    Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, Schudt C, Ermert L, Seeger W, Grimminger F.
    Circ Res; 2004 Apr 30; 94(8):1101-8. PubMed ID: 15031263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.